Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
| Egile nagusia: | Hoque, Ismoth Ara |
|---|---|
| Beste egile batzuk: | Azam, Faruque |
| Formatua: | Thesis |
| Hizkuntza: | English |
| Argitaratua: |
Brac University
2024
|
| Gaiak: | |
| Sarrera elektronikoa: | http://hdl.handle.net/10361/23164 |
Antzeko izenburuak
-
Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
nork: Paul, Pulock
Argitaratua: (2024) -
Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
nork: Rahman, Tasnim
Argitaratua: (2024) -
Pooled analysis of response rate and overall survival of Tyrosine Kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
nork: Karim, Samia Binte
Argitaratua: (2024) -
Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
nork: Flora, Sanzida Alam
Argitaratua: (2024) -
Molecules associated with the development of lung cancer
nork: Rahman, Adree, et al.
Argitaratua: (2023)